Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozurdex for CME and DME after cataract surgery
NCT01284478Phase 2Completed
- Sponsor
- Northern California Retina Vitreous Associates
- Start
- Jan 2011
- Primary completion
- Oct 2012
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ozurdex in pseudophakic cystoid macular edema (PCME) and diabetic macular edema (DME), sponsored by Northern California Retina Vitreous Associates. Primary endpoint: Best Corrected Visual Acuity at 180 days. Started Jan 2011; status: completed.
02
Drugs
ozurdex
03
Conditions
pseudophakic cystoid macular edema (PCME)diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT01284478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01284478.